Roscovitine
p34/cdc2 inhibitor / Potent and selective inhibitor of cyclin-dependent kinases displaying higher potency and selectivity compared to olomoucine. p34 cdc2 IC50 = 0.2 µM. Also inhibits p33cdk2 and p33cdk51. Anti-angiogenic2. Prevents PPARγ S273 phosphorylation, promoting browning of white adipose tissue3. Enhances peripheral nerve regrowth4.
Biochemicals & reagents
186692-46-6
1) Meijer et al. (1997), Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 ; Eur. J. Biochem., 243 527 2) Liebl et al. (2011), Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases; Angiogenesis, 14 281 3) Wang et al. (2016) Browning of White Adipose tissue with Roscovitine Induces a Distinct Population of UCP1+ Adipocytes; Cell Metab. 24 835 4) Law et al. (2016) Enhancement of Peripheral Nerve Regrowth by the Purine Nucleoside Analog and Cell Cycle Inhibitor, Roscovitine; Front. Cell. Neurosci. 10 238
-20°C
TARGET: Kinase -- PATHWAY: Cell cycle; PPAR; Transcription; Apoptosis inducer -- RESEARCH AREA: Neuroscience; Cell death -- DISEASE AREA: Cancer